# ADX-629 Therapy for Sjogren-Larsson Syndrome

> **NCT05443685** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Nebraska** · enrollment: 8 (actual)

## Conditions studied

- Sjogren-Larsson Syndrome

## Interventions

- **DRUG:** ADX-629

## Key facts

- **NCT ID:** NCT05443685
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-02
- **Primary completion:** 2026-04-01
- **Final completion:** 2026-04-01
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05443685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05443685, "ADX-629 Therapy for Sjogren-Larsson Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05443685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*